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P01015 Angiotensinogen precursor  AGT + + 
P00787 Cathepsin B precursor  CTSB + + 
P05371 Clusterin precursor  CLU + + 
P21180 Complement C2 precursor  C2 + + 
P08649 Complement C4 precursor  C4 + + 
P09006 
     
 
    
 
    
    
    
    
     
    
    
    
Contrapsin-like protease inhibitor 6 precursor  SERPINA3 + + 
P20305 Gelsolin precursor  GSN + + 
P19879 Mimecan precursor (Osteoglycin) OGN + +
P20961 Plasminogen activator inhibitor-1 precursor )  SERPINE1 + + 
Q62009 Osteoblast-specific factor 2 POSTN + + 
Q08519 serine proteinase inhibitor 1  PI + + 
P07214 SPARC precursor  
  
SPARC + + 
P29447 Thioredoxin 3 TRX3 + +
P16368 Metalloproteinase inhibitor 2 precursor (TIMP-2)  
 




AAC35371 CD14 CD14 + -
XP_213392 pigment epithelium-derived factor  SERPINF1 + - 
XP_226803 similar to Complement component C7 precursor  
 
C7 + - 
A32827 fetuin precursor AHSG + -
CAA29759 thyroid hormone binding protein  
 
P4HB + - 
AAA40964 C-reactive protein CRP + -






P20059 Hemopexin precursor HPX + -
AAA41081 vitamin D-binding protein 
  
GC + - 
XP_236746 tetranectin TNA + -
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AAH02356 nucleobindin 1  NUCB1 + - 
XP_236631 dystroglycan 1  DAG1 + - 
P49141     
    
   
   
 
   




CAA58858 lumican LUM + -
AAH13651 serine protease inhibitor 2-2  HTRA3 + -
PROTEASE 
P34955 Alpha-1-antiproteinase precursor   - + 
P14046  Alpha-1-inhibitor 3 precursor  MUG1 - + 
P05155 Plasma protease C1 inhibitor precursor  SERPING1 - + 
P05154 Plasma serine protease inhibitor precursor  SERPINA5 - + 
Q9VAC5 ADAM 17-like protease precursor  ADAM17 - + 
Q9P0K1 ADAM 22 precursor ADAM22 - + 
O15072 ADAMTS-3 precursor  ADAMTS3 - + 
P24268 Cathepsin D precursor  CTSD - + 
P08311 Cathepsin G precursor  CTSG - + 
O46427 Cathepsin H precursor  CTSH - + 
P07154 Cathepsin L precursor  CTSL - + 
Q9JL96 Cathepsin M precursor  CTSM - + 
Q60994  Adiponectin precursor * ADIPOQ - + 
Q9Z1P8 Angiopoietin-related protein 4 precursor  ANGPTL4 - + 
P08226 Apolipoprotein E precursor  APOE - + 
IMMUNE FACTORS 
 P07151 Beta-2-microglobulin precursor B2M - +
P02747 Complement C1q subcomponent, C chain precursor C1QC - + 
Q8CG16 Complement C1r-A subcomponent precursor  C1R - + 
Q6P6T1 Complement C1s subcomponent precursor C1S - + 
Q811M5 Complement component C6 precursor C6 - + 
P06682 Complement component C9 C9 - + 
P04186 Complement factor B precursor  CFB - + 
P32038 Complement factor D precursor CFD - + 
P06909 Complement factor H precursor  CFH - + 
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Q9WUW3 Complement factor I precursor  CFI - + 
INFLAMMATORY CYTOKINES    
 
 
   
   
   
     
 
    
Q61729 Interleukin-12 beta chain precursor  - + 
Q9H293 Interleukin-17E precursor  IL25 - + 
Q95141 Interferon-alpha/beta receptor beta chain precursor  IFNAR2 - + 
P34884 Macrophage migration inhibitory factor (MIF) MIF - + 
P19876 Macrophage inflammatory protein 2-beta precursor  CXCL3 - + 
P97885 Small inducible cytokine B5 precursor  CXCL6 - + 
COLLAGEN 
P02467 Collagen alpha 2(I) chain precursor  COL1A2 - + 
P01026 Complement C3 precursor C3 - + 
P02463 Collagen alpha 1(IV) chain precursor COL4A1 - + 
P08572 Collagen alpha 2(IV) chain precursor COL4A2 - + 
P15989 Collagen alpha 3(VI) chain precursor COL6A3 - + 
P25067 Collagen alpha 2(VIII) chain precursor  COL8A2 - + 
Q28902 Collagen alpha 1(XII) chain COL12A1 - + 
O35206 Collagen alpha 1(XV) chain precursor  COL15A1 - + 
P39060 Collagen alpha 1(XVIII) chain precursor  COL18A1 - + 
P08253 72 kDa type IV collagenase precursor  MMP2 - + 
P08124 Cuticle collagen 1 precursor  COL1 - + 
O19092 Cystatin C precursor CST3 - + 
EXTRACELLULAR MATRIX PROTEINS 
  P48675 Desmin DES - +
P04937 Fibronectin precursor FN1 - +
Q01129 Decorin precursor (Bone proteoglycan II)  DCN - + 
Q00174 Laminin alpha chain precursor LAMA - + 
Q16787 Laminin alpha-3 chain precursor  LAMA3 - + 
Q16363 Laminin alpha-4 chain precursor LAMA4 - + 
Q61001 Laminin alpha-5 chain precursor LAMA5 - + 
P02469 Laminin beta-1 chain precursor  
  
LAMB1 - + 
P02870 Lectin LGALS9B - +
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P36573 32 kDa beta-galactoside-binding lectin  GBP - + 
P15838 Legumin A2 precursor   - + 
Q99538 Legumain precursor  LGMN - + 
P30120 Metalloproteinase inhibitor 1 precursor (TIMP-1) 
 
TIMP1 - + 
P24347 Matrix metalloproteinase-11 MMP11 - +
GROWTH FACTORS 
O77681 Growth/differentiation factor 9 precursor   - + 
P17936 









P01343 Insulin-like growth factor IA precursor  IGF1 - + 
OTHERS 
O08619 Coagulation factor XIII A chain precursor  F13A1 - + 
P19540 Coagulation factor IX precursor  F9 - + 
Q62959 Leptin receptor precursor LEPR? - + 
P11151 Lipoprotein lipase precursor  LPL - + 
Q9BGI2 Peroxiredoxin 4  PRDX4 - + 





P34740 Syndecan-1 precursor - +
P35441 Thrombospondin-1 precursor THBS1 - +
P49746 Thrombospondin-3 precursor THBS3 - +
Q9UBV4 Wnt-16 protein precursor WNT16 - + 
P28133 Wnt-3a protein (Fragment) WNT3A - + 
Note: Proteins were identified from the medium conditioned with epididymal adipose tissue of Zucker obese rats  
          with or without TZD treatment.   
 
Figure S1.  Glucose tolerant test in Zucker obese rats with rosiglitazone treatment.  (A) 
Zucker obese rats with a 4 day treatment of rosiglitazone have no significant 
improvement in glucose tolerance.  (B) Zucker obese rats with 12 day treatment of 
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Table S2.  Metabolic parameters in Zucker obese rats before and  
after Rosiglitazone treatment for 12 days  
 
Treatment  NT Rosi 
Plasma glucose (mg/dl) 
(fasted) 150 ± 5.03 132 ±15.82 
Plasma TG  
(mg/dl) 300.78 ± 38.50 153.33 ± 19.42*  
Plasma FFA  
(mM) 0.70 ± 0.12 0.39 ±  0.11* 
Plasma adiponectin 
(µg/mL) 9.05 ± 0.73 11.71 ± 0.54*  
Plasma levels of glucose, TG, FFA, and adiponectin were  
measured in Zucker obese rats (n = 8-12 rats from four experiments,  
3 rats per group in each experiment) before and after treatment of  
Rosiglitazone for 12 days. Rats were fed a normal rodent diet, as  
described in material and methods section.  Statistical analysis was  








Table S3. Functional Analysis of TZD-Regulated Secretory Molecules From Obese 
Adipose Tissue 
 





B2M, APOE, SERPING1, COL4A1, FN1, LEPR, 
C1S, CLU, MMP2, IGFBP7, COL1A2, CTSD, IGF1, 
TIMP1, LPL, IGFBP3, SERPINE1, SERPINA3N, 
TIMP2, AGT 
Metabolic Disease 4.59E-13-1.77E-04 
B2M, APOE, SERPING1, FN1, COL4A1, THBS1, 
LEPR, C1S, CLU, MMP2, IGFBP7, COL1A2, 
CTSD, ANGPTL4, IGF1, TIMP1, LPL, IGFBP3, 
SERPINE1, SERPINA3N, AGT 
Immunological Disease 2.8E-12-1.67E-04 
B2M, APOE, SERPING1, FN1, LEPR, CLU, 
COL4A2, IGFBP7, IL25, C1R, COL1A2, CTSD, 
CXCL3, IGF1, TIMP1, CFH, TIMP2, AGT, MIF, 
THBS1, DCN, C1S, VIM, MMP2, CXCL6, IGFBP3, 
C4A, C6 
Immune Response 1.36E-09-1.5E-04 
B2M, LAMA5, APOE, SERPING1, MIF, COL4A1, 
FN1, THBS1, CLU, CTSG, MMP2, IL25, CXCL6, 
CTSL2, CXCL3, IGF1, TIMP1, PROS1, CTSB, F9, 
C6, TIMP2, AGT 
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Inflammatory Disease 2.5E-09-8.57E-06 
B2M, APOE, MIF, FN1, THBS1, LEPR, CLU, VIM, 
MMP2, IGFBP7, COL4A2, IL25, CXCL6, C1R, 
CTSD, CXCL3, IGF1, TIMP1, POSTN, IGFBP3, 
C4A, CFH, AGT, TIMP2 




COL8A2, APOE, FN1, LEPR, PRDX4, CLU, 
COL4A2, IGFBP7, CTSL2, CTSD, CXCL3, LGMN, 
ANGPTL4, IGF1, TIMP1, POSTN, LAMB1, 
MMP11, SERPINE1, TIMP2, AGT, LAMA5, MIF, 
COL4A1, THBS1, DCN, VIM, MMP2, LAMA4, 
LAMA3, IGFBP3, CTSB, SPARC 
Cardiovascular Disease 3.67E-09-2.99E-04 
B2M, APOE, ADAM17, FN1, LEPR, CLU, CTSG, 
CTSL2, CTSD, ANGPTL4, IGF1, TIMP1, PROS1, 
LPL, POSTN, MMP11, SERPINE1, AGT, TIMP2, 
COL4A1, THBS1, F13A1, MMP2, LAMA4, CTSB 
Immune and Lymphatic 




B2M, LAMA5, APOE, MIF, FN1, LEPR, THBS1, 
IL25,  







APOE, MIF, FN1, LEPR, MMP2, IGFBP7, CXCL3, 
IGF1, LPL, IGFBP3, SPARC, SERPINE1, AGT, 
TIMP2 
Carbohydrate Metabolism 6.35E-07-2.94E-04 
APOE, LAMA5, MIF, SERPING1, FN1, THBS1, 
LEPR, CTSG, MMP2, CTSD, IGF1, LPL, CTSB, 
SERPINE1, AGT 
Infectious Disease 1.34E-06-2.18E-04 
APOE, FN1, C1S, CLU, CXCL6, C1R, TIMP1,  
CFI, CTSB, F9, SPARC, SERPINE1, TIMP2 
Amino Acid Metabolism 2.43E-06-2.02E-04 IGF1, IGFBP3, AGT 
Lipid Metabolism 3.25E-06-1.5E-04 
APOE, MIF, ANGPTL4, IGF1, LEPR, LPL, VIM, 
IGFBP7, AGT 





2.61E-04 FN1, IGF1, LEPR, IGFBP3, CLU, AGT 
Cellular Function and 
Maintenance 
7.51E-05-






Table S4.  Pathway Analysis of TZD-Regulated Secretory Molecules From Obese 
Adipose Tissue 
 
Pathway  -Log(P-value) Ratio Molecules 
Complement System 1.34E+01 2.50E-01 C1R, CFD, SERPING1, C1S, C4A, CFI, C1QC, CFH, C6 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 7.95E+00 6.67E-02 
COL1A2, FN1, IGF1, LEPR, 
TIMP1, IGFBP3, MMP2, TIMP2, 
AGT 
Acute Phase Response 
Signaling 4.74E+00 3.98E-02 
C1R, SERPING1, FN1, C1S, 
C4A, SERPINE1, AGT 
Coagulation System 4.56E+00 1.08E-01 PROS1, F9, F13A1, SERPINE1 
IGF-1 Signaling 2.03E+00 3.23E-02 IGF1, IGFBP3, IGFBP7 
Leukocyte Extravasation 
Signaling 1.87E+00 2.07E-02 TIMP1, MMP2, MMP11, TIMP2 
LXR/RXR Activation 1.33E+00 2.35E-02 APOE, LPL 
Neuregulin Signaling 1.16E+00 2.15E-02 ADAM17, DCN 
Axonal Guidance Signaling 9.78E-01 1.02E-02 ADAM17, ADAM22, IGF1, WNT16 
Phenylalanine Metabolism 8.12E-01 9.35E-03 MIF 
Antigen Presentation Pathway 7.77E-01 2.56E-02 B2M 
Notch Signaling 7.56E-01 2.44E-02 ADAM17 
Tyrosine Metabolism 5.87E-01 5.38E-03 MIF 
IL-4 Signaling 5.51E-01 1.43E-02 B2M 
Huntington's Disease Signaling 5.39E-01 8.62E-03 CTSD, IGF1 
Ceramide Signaling 4.99E-01 1.22E-02 CTSD 
VDR/RXR Activation 4.89E-01 1.25E-02 IGFBP3 
Caveolar-mediated 
Endocytosis 4.89E-01 1.23E-02 B2M 
TGF-β Signaling 4.89E-01 1.20E-02 SERPINE1 
Role of Pattern Recognition 
Receptors in Recognition of 
Bacteria and Viruses 
4.80E-01 1.18E-02  C1QC 
FXR/RXR Activation 4.55E-01 1.00E-02  APOE 
Glucocorticoid Receptor 
Signaling 4.53E-01 7.27E-03  SERPINE1, AGT 
p53 Signaling 4.47E-01 1.15E-02  THBS1 
Glycerolipid Metabolism 4.47E-01 6.90E-03  LPL 
Amyotrophic Lateral Sclerosis 
Signaling 4.39E-01 9.26E-03  IGF1 
Aryl Hydrocarbon Receptor 
Signaling 3.03E-01 6.58E-03  CTSD 
Synaptic Long Term 
Depression 3.01E-01 6.21E-03  IGF1 
14-3-3-mediated Signaling 2.68E-01 6.41E-03  VIM 
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Clatrin-mediated Endocytosis 2.66E-01 6.06E-03  IGF1 
Wnt/β -catenin Signaling 2.57E-01 6.06E-03  WNT16 
RAR Activation 2.43E-01 5.49E-03  IGFBP3 
IL-8 Signaling 2.43E-01 5.46E-03  MMP2 
PPARα/RXRα Activation 2.41E-01 5.49E-03  LPL 
Protein Ubiquitination Pathway 2.21E-01 4.95E-03  B2M 
LPS/IL-1 Mediated Inhibition 
of RXR Function 2.08E-01 5.05E-03  APOE 
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